Drug Profile
EF 5077
Latest Information Update: 30 May 2001
Price :
$50
*
At a glance
- Originator Nonindustrial source
- Class Antiplatelets; Vascular disorder therapies
- Mechanism of Action GPIIb-IIIa antagonists
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
Highest Development Phases
- No development reported Thrombosis
Most Recent Events
- 30 May 2001 Profile reviewed but no significant changes made
- 22 Sep 1998 No-Development-Reported for Thrombosis in Japan (Unknown route)
- 08 Nov 1995 Preclinical development for Thrombosis in Japan (Unknown route)